Drugs Made In America Acquisition Corp.

Drugs Made In America Acquisition Corp. (Nasdaq: DMAAR) is a blank-check company that completed its initial public offering in 2021, targeting acquisition opportunities in the pharmaceutical and domestic drug manufacturing sector. The company filed a Form 10-Q with the SEC on May 14, 2026, reflecting its continued pre-combination status as it pursues a suitable business combination target. DMAAR's sector focus on U.S.-based pharmaceutical development and manufacturing aligns with sustained legislative and investor interest in onshoring domestic drug supply chains. For full filing history, sponsor details, deal analytics, and real-time alerts on DMAAR and hundreds of active SPACs, sign up for complete access at SpacDesk.